Form 8K Bluebird bio Inc For: 2 June
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bluebird bio Inc (BLUE)
Bluebird bio Inc stock price live, this page displays NASDAQ BLUE stock exchange data. View the BLUE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Bluebird bio Inc real time stock price chart below.
What Is the Bluebird bio Inc Stock Price Today?
The Bluebird bio Inc stock price today is 4.9700.
What Is the Stock Symbol for Bluebird bio Inc?
The stock symbol for Bluebird bio Inc is ""BLUE.""
What Stock Exchange Does Bluebird bio Inc Trade On?
Bluebird bio Inc is listed and trades on the NASDAQ stock exchange.
Is Bluebird bio Inc a Good Stock to Buy?
Determining whether Bluebird bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLUE quote. (ISIN: US09609G2093)
What Is the Bluebird bio Inc Stock Price Today?
The Bluebird bio Inc stock price today is 4.9700.
What Is the Stock Symbol for Bluebird bio Inc?
The stock symbol for Bluebird bio Inc is ""BLUE.""
What Stock Exchange Does Bluebird bio Inc Trade On?
Bluebird bio Inc is listed and trades on the NASDAQ stock exchange.
Is Bluebird bio Inc a Good Stock to Buy?
Determining whether Bluebird bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLUE quote. (ISIN: US09609G2093)
4.9700
0.0000(0.00%)
Real-time Data·
Fair Value
An estimate of a Bluebird's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.6700
5.0300
52 wk Range
3.2000
28.6000
Showing Bluebird historical data. For real-time data please try another search
Fair Value
An estimate of a Bluebird's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.67005.0300
52 wk Range
3.200028.6000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BLUE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Bluebird's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Currently not supported.
- bluebird bio acquired to scale gene therapy access
- Investing.com
- Form 8K Bluebird bio Inc For: 2 June
- Investing.com
- bluebird bio acquired to scale gene therapy access
- Investing.com
- Carlyle and SK Capital to acquire bluebird bio
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Bluebird bio Inc Company Profile
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. As of May 29, 2025, bluebird bio, Inc. was taken private.
Bluebird bio Inc SWOT Analysis
Financial Tightrope | luebird bio faces critical cash constraints, with resources projected to last only until Q2 2025, raising concerns about long-term viability and product launch execution |
Gene Therapy Promise | Explore bluebird's innovative treatments for genetic diseases, including Lyfgenia for sickle cell disease, which show potential despite challenging market conditions |
Analyst Outlook | Price targets range from $2 to $40, reflecting diverse views on bluebird's future. Barclays maintains an Overweight rating, while RBC Capital Markets rates it Sector Perform |
Strategic Restructuring | Learn how bluebird's cost-cutting measures aim to achieve cash flow break-even by H2 2025, balancing financial stability with the need for effective product launches |
Bluebird bio Inc Earnings Call Summary for Q3/2024
- Patient starts more than doubled to 57 in Q3; Q4 revenue expected to rebound to $25M+ despite Q3 decline to $10.6M
- Cash flow breakeven targeted for H2 2025, contingent on securing additional funding; 20% reduction in operating expenses planned
- Over 50% of U.S. states confirm coverage for LYFGENIA; manufacturing capacity to double by 2026 to meet demand
- Reverse stock split proposed to regain NASDAQ compliance; shareholder meeting scheduled for December 4
- Company managing cash gap anticipated in Q2 2025 through contract renegotiations and partnerships
Last Updated: 14/11/2024, 21:58
Read Full TranscriptCompare BLUE to Peers and Sector
Metrics to compare | BLUE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLUEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −5.8x | −0.5x | |
PEG Ratio | 0.00 | 0.01 | 0.00 | |
Price/Book | −0.8x | 3.0x | 2.6x | |
Price / LTM Sales | 0.5x | 4.6x | 3.2x | |
Upside (Analyst Target) | 61.0% | 131.2% | 41.6% | |
Fair Value Upside | Unlock | 11.6% | 6.0% | Unlock |
Earnings
Latest Release
May 14, 2025
EPS / Forecast
-2.98 / -0.1983
Revenue / Forecast
38.71M / 34.61M
People Also Watch
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.